These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1167 related items for PubMed ID: 19396723

  • 21. Usefulness of naftopidil for dysuria in benign prostatic hyperplasia and its optimal dose--comparison between 75 and 50 mg.
    Oh-oka H.
    Urol Int; 2009; 82(2):136-42. PubMed ID: 19321997
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A, Wyndaele JJ, Sieber P.
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [Additional effect of propiverine for naftopidil-resistant nocturia in the patient with benign prostate hypertrophy].
    Kamimura N, Hatakeyama S, Kudo S, Yoneyama T, Hashimoto Y, Koie T, Yoshikawa K, Kawaguchi T, Takahashi S, Ohyama C.
    Hinyokika Kiyo; 2011 Feb; 57(2):71-6. PubMed ID: 21412038
    [Abstract] [Full Text] [Related]

  • 26. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.
    Rovner ES, Kreder K, Sussman DO, Kaplan SA, Carlsson M, Bavendam T, Guan Z.
    J Urol; 2008 Sep; 180(3):1034-41. PubMed ID: 18639297
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Clinical effect of naftopidil on the quality of life of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective study.
    Komiya A, Suzuki H, Awa Y, Egoshi K, Onishi T, Nakatsu H, Ohki T, Mikami K, Sato N, Araki K, Ota S, Naya Y, Ichikawa T.
    Int J Urol; 2010 Jun; 17(6):555-62. PubMed ID: 20370847
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR, Van Kerrebroeck PE, Jünemann KP, Wang JT, Brodsky M.
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [Abstract] [Full Text] [Related]

  • 37. A randomised, prospective double-blind, propiverine-controlled trial of imidafenacin in patients with overactive bladder.
    Park C, Park J, Choo MS, Kim JC, Lee JG, Lee JZ, Lee KS, Kim DY, Lee SJ, Seo JT.
    Int J Clin Pract; 2014 Feb; 68(2):188-96. PubMed ID: 24373019
    [Abstract] [Full Text] [Related]

  • 38. Effects of propiverine and naftopidil on the urinary ATP level and bladder activity after bladder stimulation in rats.
    Sugaya K, Nishijima S, Tasaki S, Kadekawa K, Miyazato M, Ogawa Y.
    Neurosci Lett; 2007 Dec 18; 429(2-3):142-6. PubMed ID: 17997223
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study.
    Alloussi S, Mürtz G, Braun R, Gerhardt U, Heinrich M, Hellmis E, Horn W, Marschall-Kehrel D, Niklas K, Raabe M, Rössler T, Seibt B, Siemer S, Schultz-Lampel D, Walter H, Wiedeking B, Alloussi S, Bock P, Strugala G, Madersbacher H.
    BJU Int; 2010 Aug 18; 106(4):550-6. PubMed ID: 20002668
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 59.